

								SHEE	<u>r 10f 1</u>
INFORMATION DISCLOSURE STATEMENT PTO-1449			ATTY. DOCKET NO.			SERIAL NO.			
			GNE-290.041 US			10/617,573			
			APPLICANT Ellen Filvaroff, et al.						
			FILING DATE 07/11/2003			GROUP: 1646			
		FOR	EIC	ON PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY		CLASS		SUBCLASS	TRANSLATION	
								YES	NO
	WO 00/15798	03/23/2000						\boxtimes	
	WO 00/42188	07/20/2000						\boxtimes	
	WO 01/12659	02/22/2001						\boxtimes	
	WO 01/48192	07/05/2001				•		\boxtimes	
,	WO 01/68859	09/20/2001						\boxtimes	
	WO 01/93983	12/13/2001						\boxtimes	
	WO 02/08259	01/31/2002						\boxtimes	
	WO 02/08288 01/31/2002							☒	
	OTHER DO	CUMENTS	(Inc	luding Author, Title, Date, Po	ertine	nt Pa	ges, Etc.)		
	Database – "Ho AY359113, 10/		one	DNA173894 IL17D (UNQ309	6) mI	RNA,	complete cds",	Accession	n No.
	Database – "Homo sapiens clone RP11-12K9, working draft sequence, 14 unordered pieces", Accorda AC018392, 12/14/1999								sion No.
	Database – "Ho No. AL133097		RN.	A; cDNA DKFZp434N1928 (fi	rom c	lone I)KFZp434N192	8)", Acc	ession
				tor D precursor (IL-17 receptor og) (hSef)", Accession No. Q81) (Interle	ukin-17
	Database - "Int 06/01/2002	erleukin-17D	prec	cursor (IL-17D) (Interleukin-27) (IL-	27)",	Accession No. (Q8TAD2	,
Database – "w172f12.z1 NCI_CGAP_Brn25 Homo sapiens cDNA clone IMAGE:2430479 3', mRNA sequence", Accession No. AI870335, 07/22/1999									Α
	Database – "zf42f08.s1 Soares_fetal_heart_NbHH19W Homo sapiens cDNA clone IMAGE:379623 3', mRNA sequence", Accession No. AA778029, 02/06/1998 Starnes, et al., "Cutting edge: IL-D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis" Journal of Immunology, Vol. 169, No. 2, pages 642-646, (2002)								
		es basic fibrob	last	-17 receptor-like protein identification growth factor-induced signalin (2003)					
FXAMINER				DATE CONSIDERED					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.